Atea Pharmaceuticals Inc. Common Stock (AVIR)

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-58…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

55

Website

ateapharma.com/

Fundamentals

1-day range

$5.36$5.59

Market cap

$399.34M

P/E (trailing)

—

P/E (forward)

-3.76

EPS (trailing)

$-2.12

Dividend yield

—

Beta

0.40

Avg. volume

340.9K

Forecasts

3 analyst ratings

Atea Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AVIR

  Atea Pharmaceuticals Inc. Common Stock

  $5.36

  ▼ 1.65%
  Market cap $399.34MP/E —
  $2.78$6.45
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $387.91MP/E —
  $7.05$17.15
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $386.55MP/E —
  $2.53$5.45
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $413.30MP/E 18.65
  $4.3$9.51
• ASMB

  Assembly Biosciences Inc. Common Stock

  $33.97

  ▼ 2.39%
  Market cap $420.36MP/E 333.50
  $20.23$39.71
• UPB

  Upstream Bio Inc. Common Stock

  $6.68

  ▼ 1.62%
  Market cap $373.87MP/E —
  $5.85$33.68
• DMAC

  DiaMedica Therapeutics Inc. Common Stock

  $6.39

  ▼ 5.33%
  Market cap $364.79MP/E —
  $5.14$10.42

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

58.19M

Total value held

$303.50M

Institutional holders

123